ARCHIVES

FDA Approval Of Two Generic Versions Of Taxol Likely To End BMS Exclusivity.

This article is from The Cancer Letter archive.

Vol. 26 No. 35 | September 29, 2000

Download PDF Visit The Full Archive

Related Articles

NIH Bias Against Young Investigators Threatens To “Deprime The Pump,” Zerhouni Says.

February 15, 2008

RFPs Go Out To Cooperative Groups for Community Programs

April 9, 1976

FDA News: Zydelig approved in three B-cell blood cancers

August 1, 2014

Foundation Honors Three In Oncology; Society Wins Software Grant From Microsoft.

October 26, 2001

Kimes Heads NCI Organ Systems Committee; Changes Being Implemented

April 1, 1988

New RFAs on Retinoids & Carotenoids, Tobacco, NMR Research Resistance

July 27, 1984